Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Regorafenib in Advanced Cholangiocarcinoma (REACHIN)
NCT02162914Phase 2Unknown
- Sponsor
- Erasmus Hospital
- Start
- Mar 2014
- Primary completion
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of regorafenib in intrahepatic cholangiocarcinoma (ICC), hilar cholangiocarcinoma (HC), sponsored by Erasmus Hospital. Status: unknown.
02
Drugs
regorafenib
03
Conditions
intrahepatic cholangiocarcinoma (ICC)hilar cholangiocarcinoma (HC)
Beyond the preview
Go deeper on NCT02162914.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02162914.